Doo Cho, MD
Neurodevelopmental Disabilities · Johnstown, PANPI 1609891662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 598 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,433, 3.9 times the $625 reported in 2019.
Across 598 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$972
- Johnson & Johnson$870
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$855
- Alkermes, Inc.$578
- plus $3K from 17 others
What the payments were for
- Food & beverage$8,97399%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 163 | $1,839 |
| Otsuka America Pharmaceutical, Inc. | 64 | $1,124 |
| Teva Pharmaceuticals USA, Inc. | 75 | $972 |
| Johnson & Johnson | 67 | $870 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $855 |
| Alkermes, Inc. | 31 | $578 |
| Neurocrine Biosciences, Inc. | 25 | $501 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $387 |
| Axsome Therapeutics, Inc. | 15 | $326 |
| E.r. Squibb & Sons, L.L.C. | 18 | $323 |
| Lundbeck LLC | 15 | $289 |
| Sunovion Pharmaceuticals Inc. | 15 | $191 |
| Merck | 9 | $150 |
| Ironshore Pharmaceuticals Inc. | 5 | $130 |
| Supernus Pharmaceuticals, Inc. | 7 | $130 |
| Corium, LLC | 6 | $103 |
| Vanda Pharmaceuticals Inc. | 4 | $77 |
| Noven Therapeutics, LLC | 3 | $65 |
| Eisai Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Shire North American Group Inc | 2 | $24 |
| Indivior Inc. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $14 |
How this compares
Too few neurodevelopmental disabilities providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 13 | $28,137 |
| VraylarCariprazine Hcl | 13 | $20,839 |
| Lurasidone Hcl | 60 | $14,278 |
| Aripiprazole | 193 | $8,961 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $8,306 |
| Paliperidone ErPaliperidone | 24 | $7,974 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 262 | $6,090 |
| FetzimaLevomilnacipran Hcl | 12 | $5,831 |
| Perphenazine | 133 | $5,808 |
| Vilazodone Hcl | 61 | $4,814 |
| Bupropion XlBupropion Hcl | 151 | $3,913 |
| Gabapentin | 257 | $3,589 |
| Clonazepam | 518 | $3,364 |
| Lisdexamfetamine Dimesylate | 13 | $2,865 |
| Duloxetine Hcl | 205 | $2,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $870 | $28,13713 claims |
| AbbVieVraylar, Fetzima | $1,839 | $26,67125 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $387 | $8,30617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurodevelopmental disabilities providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other neurodevelopmental disabilities in Johnstown
- Ashutosh KumarHershey$307K
- Sita PaudelHershey$808
- Gozde ErdemirHershey$729
- Sunil NaikHershey$497
- William TrescherHershey$142
- Kate KieltyPittsburgh$134
- Thomas CaseyBryn Mawr$94
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.